Immunocore Holdings PLC (IMCR)
32.12
-0.30
(-0.93%)
USD |
NASDAQ |
Nov 21, 16:00
32.06
-0.06
(-0.19%)
After-Hours: 20:00
Immunocore Holdings Enterprise Value: 1.159B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 1.159B |
| November 19, 2024 | 1.166B |
| November 18, 2024 | 1.091B |
| November 15, 2024 | 1.118B |
| November 14, 2024 | 1.169B |
| November 13, 2024 | 1.247B |
| November 12, 2024 | 1.226B |
| November 11, 2024 | 1.271B |
| November 08, 2024 | 1.273B |
| November 07, 2024 | 1.254B |
| November 06, 2024 | 1.214B |
| November 05, 2024 | 1.188B |
| November 04, 2024 | 1.097B |
| November 01, 2024 | 1.123B |
| October 31, 2024 | 1.080B |
| October 30, 2024 | 1.134B |
| October 29, 2024 | 1.174B |
| October 28, 2024 | 1.205B |
| October 25, 2024 | 1.178B |
| October 24, 2024 | 1.163B |
| October 23, 2024 | 1.139B |
| October 22, 2024 | 1.204B |
| October 21, 2024 | 1.204B |
| October 18, 2024 | 1.257B |
| October 17, 2024 | 1.226B |
| Date | Value |
|---|---|
| October 16, 2024 | 1.202B |
| October 15, 2024 | 1.154B |
| October 14, 2024 | 1.148B |
| October 11, 2024 | 1.093B |
| October 10, 2024 | 1.083B |
| October 09, 2024 | 1.038B |
| October 08, 2024 | 1.067B |
| October 07, 2024 | 1.076B |
| October 04, 2024 | 1.094B |
| October 03, 2024 | 1.063B |
| October 02, 2024 | 1.093B |
| October 01, 2024 | 1.099B |
| September 30, 2024 | 1.095B |
| September 27, 2024 | 1.149B |
| September 26, 2024 | 1.118B |
| September 25, 2024 | 1.112B |
| September 24, 2024 | 1.082B |
| September 23, 2024 | 1.119B |
| September 20, 2024 | 1.238B |
| September 19, 2024 | 1.290B |
| September 18, 2024 | 1.301B |
| September 17, 2024 | 1.274B |
| September 16, 2024 | 1.229B |
| September 13, 2024 | 1.257B |
| September 12, 2024 | 1.230B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
559.95M
Minimum
Jan 20 2022
3.360B
Maximum
Feb 07 2024
1.824B
Average
1.786B
Median
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 33.86M |
| Biodexa Pharmaceuticals PLC | -3.674M |
| Verona Pharma PLC | 2.963B |
| NuCana PLC | -11.85M |
| Autolus Therapeutics PLC | 88.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.736M |
| Revenue (Quarterly) | 80.25M |
| Total Expenses (Quarterly) | 88.75M |
| EPS Diluted (Quarterly) | 0.17 |
| Gross Profit Margin (Quarterly) | 99.44% |
| Profit Margin (Quarterly) | 10.89% |
| Earnings Yield | -2.96% |
| Normalized Earnings Yield | -2.395 |